Stock comparison
Mettler-Toledo International
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$5.95B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 49D | MTD |
| Benjamin Graham | 65B | 62D | MTD |
| Philip Fisher | 63C | 54C | MTD |
| Peter Lynch | 66B | 80A | TGTX |
| Joel Greenblatt | 68B | 63C | MTD |
| Charlie Munger | 74B | 52D | MTD |
| Terry Smith | 70B | 44D | MTD |
Side-by-side metrics
| Metric | MTD | TGTX |
|---|---|---|
| Market cap | $22.29B | $5.95B |
| P/E (TTM) | 25.3x | 13.3x |
| EV/EBIT | 21.6x | 55.3x |
| ROIC (TTM) | 36.09% | 11.13% |
| Gross margin | 57.79% | 83.04% |
| Net margin | 21.4% | 65.95% |
| Revenue CAGR 5y | 2.01% | 2.1% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 1.3x+102%
- Market cap$22.29Bvs $5.95B+73%
- ROIC (TTM)36.09%vs 11.13%+69%
- EV/EBIT21.6xvs 55.3x+61%
TGTX leads on
- Revenue CAGR 5y2.1%vs 2.01%+99%
- Net margin65.95%vs 21.4%+68%
- P/E (TTM)13.3xvs 25.3x+47%
- Gross margin83.04%vs 57.79%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.